Revelation Biosciences Receives Approval To Initiate Phase 2B Viral Challenge Study Of REVTx 99 For Prevention Of Respiratory Viral Infections

T-Reuters
28 Sep 2021

Petra Acquisition Inc :Revelation Biosciences Inc. Receives Approval To Initiate Phase 2B Viral Challenge Study Of Revtx 99, An Experimental Prophylactic Treatment For Prevention Of Respiratory Viral Infections.Petra Acquisition Inc - Phase 2B Study Will Investigate Efficacy Of Revtx-99 On Viral Load And Patient-Reported Flu Symptoms.Petra Acquisition Inc - Top-Line Data Anticipated In Q2 Of 2022.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10